Discover 1,955 paid clinical trials in Denton, Texas. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,955
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
for
HER2-positive Breast Cancer, Breast Cancer
Location: Dallas TX, Shreveport LA, Houston TX, San Antonio TX,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07102381
Phase 2, Recruiting
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
for
Von Willebrand Disease (VWD)
Location: Dallas TX, Little Rock AR, Atlanta GA, Minneapolis MN,
Sponsor: Vega Therapeutics, Inc
Sex: All
Age: 12 - 70+
Code: NCT07115004
Phase 3, Recruiting
AERA Pediatrics Registry
for
Dysfunction of Eustachian Tube
Location: Fort Worth TX, Houston TX, Cincinnati OH,
Sponsor: Integra LifeSciences Corporation
Sex: All
Age: 0 - 18
Code: NCT07071298
Recruiting
Radiation Free Study
for
Aortic Aneurysm
Location: Dallas TX, Birmingham AL, Philadelphia PA, Worcester MA
Sponsor: Philips Clinical & Medical Affairs Global
Sex: All
Age: 18+
Code: NCT06549348
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
for
Metastatic Castration-resistant Prostate Cancer
Location: Dallas TX, Arlington TX, Tyler TX, Oklahoma City OK,
Sponsor: Amgen
Sex: Male
Age: 18+
Code: NCT07213674
Phase 3, Recruiting
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
for
Metastatic Castration-Resistant Prostate Cancer
Location: Dallas TX, Houston TX, New Orleans LA, Albuquerque NM,
Sponsor: Kyntra Bio
Sex: Male
Age: 18+
Code: NCT06842498
Phase 2, Recruiting
Regeneration of Acutely Injured Nerves With Temporary Electrical Stimulation
for
Nerve Injury
Location: Fort Worth TX, New Orleans LA, Gainesville FL,
Sponsor: Epineuron Technologies Inc.
Sex: All
Age: 18 - 65
Code: NCT05721261
Recruiting
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
Sponsor: University of Texas Southwestern Medical Center
Sex: All
Age: 11+
Code: NCT03428009
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
for
HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC),
Location: Dallas TX, Houston TX, San Antonio TX, St Louis MO,
Sponsor: NiKang Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07029399
Phase 1, Recruiting
Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis
for
Locally Advanced Renal Cell Carcinoma
Location: Dallas TX, St Louis MO, Richmond VA
Sponsor: Qian Qin
Sex: All
Age: 18+
Code: NCT06794229
Phase 2, Recruiting
VOICE: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for Communication Restoration
for
Tetraplegia/Tetraparesis, Quadriplegia,
Location: Dallas TX
Sponsor: Neuralink Corp
Sex: All
Age: 22 - 70+
Code: NCT07224256
Recruiting
Comparing Outcomes Among Children With Obesity in a Community Healthy Lifestyle Program
Sponsor: University of Texas Southwestern Medical Center
Sex: All
Age: 6 - 14
Code: NCT07342855
Recruiting
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
for
Mild Autonomous Cortisol Secretion (MACS),
Location: Dallas TX
Sponsor: University of Texas Southwestern Medical Center
Sex: All
Age: 18+
Code: NCT07361874
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
for
Pancreatic Cancer, PDAC,
Location: Dallas TX, Longview TX, Lawrence KS, Kansas City MO,
Sponsor: Revolution Medicines, Inc.
Sex: All
Age: 18+
Code: NCT07252232
Phase 3, Recruiting
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer